{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T16:36:46Z","timestamp":1757608606237,"version":"3.44.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the application of nafamostat mesylate in the extracorporeal carbon dioxide removal combined with continuous renal replacement therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We analyzed the cases of 5 patients who underwent extracorporeal carbon dioxide removal combined with continuous renal replacement therapy due to severe hypercapnia with acute kidney injury at the Blood Purification Center of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from July 2023 to October 2024. The treatments were performed using the OMNI blood purification system (B. Braun Avitum AG, Melsungen, Germany), equipped with a PMP polymethylpentene membrane lung (1.81\u00a0m<jats:sup>2<\/jats:sup>, Eurosets Medolla, Italy), with unhumidified pure oxygen connected to the ECCO<jats:sub>2<\/jats:sub>R membrane lung via an oxygen supply device at a rate of 6\u20137\u00a0L\/min, and in series with the blood filter (OMNIFilter 16, polyethersulfone membrane, 1.6\u00a0m<jats:sup>2<\/jats:sup>). CRRT was performed using the CVVH mode, with sodium lactate replacement fluid at a flow rate of 2\u20133\u00a0L\/h. A 14Fr dual-lumen dialysis catheter (ARROW) was placed under ultrasound-guided puncture in the femoral vein. The extracorporeal blood flow was maintained between 300 and 400\u00a0mL\/min. Continuous infusion of NM (50-30\u00a0mg\/h) was used to maintain anticoagulation. Demographic and physiological data were collected (including vital signs, ventilation parameters, blood gas, electrolytes, DIC, etc.), with blood sampling points before and after the filter as well as peripheral blood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 5 patients, there were 2 males and 3 females, with an average age of 83.2 \u00b1 9.6 years old. A total of 22 treatments were administered, with an average treatment time of 8.8 \u00b1 1.6\u00a0h. All patients had primary diseases of severe pneumonia and chronic obstructive pulmonary disease; among them, 4 had combined renal injury, and 3 patients were on mechanical ventilation. During the total of 22 treatments, there was 1 instance of dialyzing tube occlusion which led to the end of treatment 2\u00a0h early, while the other 21 treatments were completed smoothly, with no occlusion occurring in the filter, ECCO<jats:sub>2<\/jats:sub>R membrane lung, or dialyzing tube. No adverse events such as bleeding occurred in the patients, and there were no statistically significant differences in APTT and PT after treatment compared to before. During the treatment, statistically significant improvements in PaCO<jats:sub>2<\/jats:sub> and blood pH were observed. Blood pressure, heart rate, and blood oxygen saturation remained stable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Extracorporeal carbon dioxide removal combined with continuous renal replacement therapy can partially replace lung ventilation function and improve hypercapnia. NM can be used as an anticoagulant in this technology, with an ideal anticoagulation effect and no significant risk of bleeding.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1592562","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T05:37:13Z","timestamp":1756877833000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Application of nafamostat mesylate in 5 cases of extracorporeal carbon dioxide removal combined with continuous renal replacement therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Ma","family":"Xiaobo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Qiuxin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhenhua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan","family":"Xiaoting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Xiaonong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s13054-020-03210-z","article-title":"ECCO2R therapy in the ICU: consensus of a European round table meeting","volume":"24","author":"Combes","year":"2020","journal-title":"Crit. Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1051\/ject\/201749257","article-title":"Quantification of carbon dioxide removal at low sweep gas and blood flows","volume":"49","author":"de Villiers Hugo","year":"2017","journal-title":"J. Extra Corpor. Technol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"654658","DOI":"10.3389\/fmed.2021.654658","article-title":"ECCO2R in 12 COVID-19 ARDS patients with extremely low compliance and refractory hypercapnia","volume":"8","author":"Ding","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jama.1986.03380070087025","article-title":"Low-frequency positive-pressure ventilation with extracorporeal CO2 removal in severe acute respiratory failure","volume":"256","author":"Gattinoni","year":"1986","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13613-021-00824-6","article-title":"The use of extracorporeal CO2 removal in acute respiratory failure","volume":"11","author":"Giraud","year":"2021","journal-title":"Ann. Intensive Care"},{"key":"B6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.5301\/IJAO.5000191","article-title":"Nafamostat mesilate for anticoagulation in continuous renal replacement therapy","volume":"36","author":"Hwang","year":"2013","journal-title":"Int. J. Artif. Organs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/MAT.0000000000000544","article-title":"Is extracorporeal CO2 removal really \u201cSafe\u201d and \u201cLess\u201d invasive? Observation of blood injury and coagulation impairment during ECCO2R","volume":"63","author":"Kalbhenn","year":"2017","journal-title":"ASAIO J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.athoracsur.2016.01.044","article-title":"Anticoagulation during extracorporeal membrane oxygenation; nafamostat mesilate versus heparin","volume":"102","author":"Lim","year":"2016","journal-title":"Ann. Thorac. Surg."},{"key":"B9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.5301\/IJAO.2011.8535","article-title":"Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study","volume":"34","author":"Maruyama","year":"2011","journal-title":"Int. J. Artif. Organs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1056\/NEJMclde1804601","article-title":"Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome","volume":"379","author":"Mi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.5301\/ijao.5000451","article-title":"Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation","volume":"38","author":"Park","year":"2015","journal-title":"Int. J. Artif. Organs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.11855\/j.issn.0577-7402.2022.02.0107","article-title":"Standardized assessment of coagulation dysfunction in critically ill patients: a consensus among Chinese experts","volume":"47","author":"Song","year":"2022","journal-title":"J. People Liberation Army Med. Corps"},{"key":"B13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1177\/0267659120906048","article-title":"Update on extracorporeal carbon dioxide removal: a comprehensive review on principles, indications, efficiency, and complications","volume":"35","author":"Staudinger","year":"2020","journal-title":"Perfusion"},{"key":"B14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3390\/membranes11080617","article-title":"New trends, advantages and disadvantages in anticoagulation and coating methods used in extracorporeal life support devices","volume":"11","author":"Willers","year":"2021","journal-title":"Membr. (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1177\/02676591221096225","article-title":"Venovenous extracorporeal CO2 removal to support ultraprotective ventilation in moderate-severe acute respiratory distress syndrome: a systematic review and meta-analysis of the literature","volume":"38","author":"Worku","year":"2023","journal-title":"Perfusion"},{"key":"B16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/MPA.0000000000000310","article-title":"Nafamostat mesilate for prevention of post-ERCP pancreatitis: a meta-analysis of prospective, randomized, controlled trials","volume":"44","author":"Yu","year":"2015","journal-title":"Pancreas"},{"key":"B17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3969\/j.issn.2096-3351.2023.05.001","article-title":"Advances in the clinical application of extracorporeal carbon dioxide removal technology","volume":"46","author":"Zhang","year":"2023","journal-title":"J. Southwest Med. Univ."},{"key":"B18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3969\/j.issn.1671-4091.2022.10.008","article-title":"Multicenter randomized controlled study of injections of methylsulfonylmethane for anticoagulation treatment in hemodialysis","volume":"21","author":"Zhuang","year":"2022","journal-title":"Chin. J. Blood Purif."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1592562\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T05:37:15Z","timestamp":1756877835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1592562\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":18,"alternative-id":["10.3389\/fphar.2025.1592562"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1592562","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"article-number":"1592562"}}